Israel - a pioneer of medical marijuana in the world (FAQ)
Izrael: odpowiedzi na najczestsze pytania i co mowia badania. u Bucha.
When most of the world treated marijuana solely as a narcotic substance, Israel was building the scientific foundations for an entire branch of medicine. Professor Raphael Mechoulam from the Hebrew University in Jerusalem isolated THC in 1964, and two decades later - along with his team - discovered anandamide and described the human endocannabinoid system. These discoveries changed the way science understands cannabis, pain, the immune system, and the brain. Israel was also the first country to build a comprehensive medical marijuana program - in place since the 1990s. This article answers the most common questions about the Israeli model, its history, and its significance for global research.
KEY INFORMATION
• Raphael Mechoulam discovered THC in 1964 and CBD - as a pioneer of cannabinoid research (Mechoulam, Gaoni, JACS 1964 - discussion PMC 2020).
• Israel launched its medical marijuana program in 1992 - as one of the first countries in the world.
• Over 100,000 registered patients benefit from the program (data 2023).
• Israel has legalized the export of medical marijuana since 2019.
• Possession of up to 15 grams for recreational use is decriminalized (fine, not a criminal case).
• EMCDDA classifies Israel as a country with one of the most advanced medical systems in the world (EMCDDA, 2023).
History: how Israel became a center for cannabinoid research
The history of Israeli medical marijuana begins in the laboratory. In 1964, Raphael Mechoulam and Yechiel Gaoni from Hebrew University in Jerusalem published a groundbreaking paper in Journal of the American Chemical Society, describing for the first time the chemical structure of delta-9-tetrahydrocannabinol - the substance responsible for the psychoactive effects of marijuana. A few years later, Mechoulam isolated and described CBD (Mechoulam, 2020 review, PMC).
Equally important was the discovery in 1992. Mechoulam, along with William Devane and Lumír Hanuš, described anandamide - the first endogenous cannabinoid molecule produced by the human body. The name comes from the Sanskrit word ananda, meaning bliss. This discovery confirmed the existence of the endocannabinoid system (ECS) - a network of CB1 and CB2 receptors distributed in the brain, immune system, and internal organs.
In parallel with scientific discoveries, Israel was building its medical infrastructure. As early as 1992, the Israeli government issued the first permits for the use of medical marijuana in cancer patients. The program was managed by the Ministry of Health and gradually expanded to include additional indications - epilepsy, PTSD, inflammatory bowel diseases, chronic pain, and others.
The Israeli medical marijuana system today
The current medical marijuana program in Israel is managed by the Israeli Cannabis Unit (ICU) within the Ministry of Health. A patient wishing to gain access must obtain a referral from a specialist doctor, who then submits an application to the ICU. The Ministry issues an individual patient license for a specified time and amount.
| System element | Details |
|---|---|
| Number of patients | over 100,000 (data 2023) |
| Medical indications | chronic pain, cancers, epilepsy, PTSD, Crohn's, MS, Parkinson's, and others |
| Distribution channels | licensed pharmacies, home delivery |
| Product forms | dried flowers, oils, extracts, capsules |
| Export (since 2019) | legalne - do Niemiec, Kanady i in. |
| Recreational possession | decriminalized up to 15 g; fine, not a criminal penalty |
| Recreational sales | illegal |
Scientific research - what is Israel studying and why is it important
Israel remains one of the global centers for cannabinoid research. The government funds clinical projects through the Israeli Cannabis Unit, and local universities publish results in prestigious scientific journals. Major research areas include treatment of neuropathic pain, applications in oncology (particularly reducing nausea after chemotherapy and cancer pain), PTSD therapy for war veterans, and childhood epilepsy.
A study published in European Journal of Pain in 2018 showed that patients with chronic pain treated with medical marijuana for six months experienced a reduction in pain intensity of over 50% alongside an improvement in quality of life (Aviram, Samuelly-Leichtag, 2017 - discussion of PMC). The study involved over 200 patients and was conducted by Israeli researchers from Technion.
In the area of PTSD, Israel is particularly active due to its large population of war veterans. A clinical study conducted at Tel Aviv University found that CBD and low-dose THC reduce the severity of nightmares and reactivity to traumatic stimuli in veterans with PTSD. The results were published in Frontiers in Psychiatry in 2020.
Israeli biotech and pharmaceutical companies, such as IMC (Israel-Canada Consortium) and BOL Pharma, conduct dozens of clinical studies annually, creating a science and business ecosystem that attracts investors and partners from around the world.
Dekryminalizacja rekreacyjna - co oznacza w praktyce
Israel has not legalized recreational marijuana, but in 2017 it decriminalized possession of small amounts. A person caught with up to 15 grams of marijuana for the first time receives an administrative fine of about 1000 shekels (approximately 1100 PLN). A second offense carries a higher monetary penalty and may lead to referral to an educational program. Only a third offense may result in criminal proceedings.
Smoking marijuana in public places is prohibited regardless of the amount. The decriminalization system applies only to possession for personal use - sale remains a criminal offense.
Frequently Asked Questions
Why is Israel considered a pioneer in medical marijuana?
Israel was the first country in the world to build a comprehensive medical marijuana program in the 1990s. The country is home to Prof. Raphael Mechoulam, who discovered THC and CBD in 1964 and later described the endocannabinoid system. Israeli regulations from 1992 allowed the use of medical marijuana by cancer patients and others, which was unprecedented on a global scale.
Who is Raphael Mechoulam and what is his significance?
Prof. Raphael Mechoulam (1930-2023) was an Israeli organic chemist recognized as the father of cannabinoid research. In 1964, he first isolated and described the chemical structure of THC, and then CBD. In 1992, his team discovered anandamide - the first endogenous cannabinoid, which initiated research on the human endocannabinoid system. Mechoulam published over 400 scientific papers.
What does the medical marijuana system in Israel look like today?
The Israeli medical marijuana system is one of the largest and most advanced in the world. The country has over 100,000 registered patients. Specialist doctors can prescribe for patients with chronic pain, cancer, epilepsy, PTSD, and other conditions. Medical marijuana can be purchased at licensed pharmacies or delivered to homes.
Is recreational marijuana legal in Israel?
No. Israel has decriminalized possession of up to 15 grams of recreational marijuana - the first offense results in an administrative fine, not criminal proceedings. However, full recreational legalization has not been implemented. The sale of marijuana outside the medical system remains illegal.
Does Israel export medical marijuana?
Yes. Israel allowed the export of medical marijuana in 2019 and is one of the leading global exporters. Products from Israeli cannabis companies are sent to countries including Germany and Canada. The value of Israeli cannabis exports is estimated to be in the hundreds of millions of dollars annually.
What research on marijuana is being conducted in Israel?
Israel has one of the strongest cannabinoid research ecosystems in the world. Research focuses on neuropathic pain, PTSD, epilepsy, inflammatory diseases, and oncology. Israeli universities (Weizmann Institute, Hebrew University, Tel Aviv University) regularly publish results in peer-reviewed journals. The government funds clinical research through the Israeli Cannabis Unit.
How does Poland compare to Israel in terms of medical marijuana?
Since 2017, Poland has allowed the import and distribution of medical marijuana by prescription from a specialist doctor. However, the number of patients is significantly lower than in Israel, and access can be hindered by a lack of reimbursement and a limited number of prescribing doctors. The Israeli model is often referenced in Polish discussions as a benchmark.
Where can reliable information about Israeli research be found?
The PubMed/NCBI database contains thousands of scientific papers by Israeli researchers on cannabinoids. The Israeli Ministry of Health publishes reports on the medical program at health.gov.il. EMCDDA monitors drug policy in Europe, including Israeli contexts in thematic reports available at emcdda.europa.eu.
The future of the Israeli model - is recreational legalization on the horizon?
The discussion about full legalization of recreational marijuana has been ongoing in the Israeli Knesset for several years. In 2022, a parliamentary committee approved a preliminary draft legalization bill, but further work was suspended due to political instability and subsequent parliamentary elections. The Israeli center-left coalition supported legalization as part of a drug law reform program; right-wing religious parties consistently oppose it.
Meanwhile, the de facto situation in the market is already partially liberalized: possession of up to 15 grams is associated with a fine, which in practice means that smoking recreational marijuana has become common and almost overt in certain circles of urban culture - especially in Tel Aviv. The police focus on more serious drug offenses, and relatively few fines are issued for possession of small amounts.
Economically, recreational legalization in Israel would have enormous significance - the Israeli cannabis market is valued at billions of dollars, and local biotech and agricultural companies are ready to immediately enter the recreational segment. Experts point out that Israel has a unique advantage: decades of scientific experience, a ready cultivation infrastructure, a licensing system, and a workforce specialized in cannabinoids. If legalization occurs, Israel has all the conditions to become one of the global leaders in the cannabis market - both medical and recreational.
For Poland and other EU countries, observing the Israeli model has cognitive value: it shows that a medical marijuana system can function effectively under strong regulatory oversight, a well-developed scientific base, and clear qualifying criteria for patients - without full recreational legalization, which remains a separate political decision.
This article is for informational and educational purposes and does not constitute legal advice. The legal status described in the article is valid as of the publication date - regulations regarding cannabis may change. Consult a lawyer or current legal acts before making decisions.
Author: Michał Waluk · Published: 2026-05-04 · Updated: 2026-05-04
